世界の重症筋無力症治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Myasthenia Gravis Disease Drugs Market Size, Status and Forecast 2021-2027

• レポートコード：QYR2104Z3982 • 出版社/出版日：QYResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、98ページ • 納品方法：Eメール（納期：3日） • 産業分類：医療

• 販売価格（消費税別）

Single User	￥565,500 (USD3,900)	▷ お問い合わせ
Multi User/Five User	￥848,250 (USD5,850)	▷ お問い合わせ
Enterprise License（同一法人内共有可）	￥1,131,000 (USD7,800)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査資料では、重症筋無力症治療薬のグローバル市場（2016年～2027年）について調べ、市場動向、主要企業の市場シェア、種類別市場規模（アセチルコリンエステラーゼ阻害剤、免疫抑制剤、ステロイド、その他）、用途別市場規模（病院、診療所、その他）、主要地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、関連企業情報などを掲載しています。 ・市場概要 ・重症筋無力症治療薬の市場動向 ・企業の競争状況、市場シェア ・重症筋無力症治療薬の種類別市場規模（アセチルコリンエステラーゼ阻害剤、免疫抑制剤、ステロイド、その他） ・重症筋無力症治療薬の用途別市場規模（病院、診療所、その他） ・重症筋無力症治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・重症筋無力症治療薬のヨーロッパ市場規模2016-2027（ドイツ、フランス、イギリス等） ・重症筋無力症治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・重症筋無力症治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・重症筋無力症治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（GlaxoSmithKline、Novartis、Teva Pharmaceutical、Roche、Bristol-Myers Squibb、Apotex、Cipla、Biogen、AbbVie、Bausch Health、Sun Pharmaceuticals） ・結論

Myasthenia gravis is a neuromuscular disorder that leads to the weakening of skeletal muscles, which are responsible for the movement of the body. This condition occurs due to the impairment of communication between muscles and nerve cells. This impairment causes difficulties in the contraction and relaxation of muscles which are crucial for carrying out daily activities, resulting in muscle weakness. It mostly affects the muscles that control the eyes and eyelids, facial expressions, chewing, and speaking.
The Americas accounted for the largest market share of the global myasthenia gravis disease market owing to the growing number of drug manufacturers, increasing awareness about the long-term effects of muscle dystrophy, and rising government funding for the treatment of this disease in the region. Moreover, the U.S. contributes to a significant market share in the global pharmaceutical industry.

Market Analysis and Insights: Global Myasthenia Gravis Disease Drugs Market
The global Myasthenia Gravis Disease Drugs market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Myasthenia Gravis Disease Drugs market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Myasthenia Gravis Disease Drugs market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Myasthenia Gravis Disease Drugs market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Myasthenia Gravis Disease Drugs market.

Global Myasthenia Gravis Disease Drugs Scope and Market Size
Myasthenia Gravis Disease Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Myasthenia Gravis Disease Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Acetylcholinesterase Inhibitors
Immunosuppressant Drugs
Steroid
Others

Segment by Application
Hospitals
Clinics
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
GlaxoSmithKline
Novartis
Teva Pharmaceutical
Roche
Bristol-Myers Squibb
Apotex
Cipla
Biogen
AbbVie

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Myasthenia Gravis Disease Drugs Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Acetylcholinesterase Inhibitors
1.2.3 Immunosuppressant Drugs
1.2.4 Steroid
1.2.5 Others
1.3 Market by Application
1.3.1 Global Myasthenia Gravis Disease Drugs Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Myasthenia Gravis Disease Drugs Market Perspective (2016-2027)
2.2 Myasthenia Gravis Disease Drugs Growth Trends by Regions
2.2.1 Myasthenia Gravis Disease Drugs Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Myasthenia Gravis Disease Drugs Historic Market Share by Regions (2016-2021)
2.2.3 Myasthenia Gravis Disease Drugs Forecasted Market Size by Regions (2022-2027)
2.3 Myasthenia Gravis Disease Drugs Industry Dynamic
2.3.1 Myasthenia Gravis Disease Drugs Market Trends
2.3.2 Myasthenia Gravis Disease Drugs Market Drivers
2.3.3 Myasthenia Gravis Disease Drugs Market Challenges
2.3.4 Myasthenia Gravis Disease Drugs Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Myasthenia Gravis Disease Drugs Players by Revenue
3.1.1 Global Top Myasthenia Gravis Disease Drugs Players by Revenue (2016-2021)
3.1.2 Global Myasthenia Gravis Disease Drugs Revenue Market Share by Players (2016-2021)
3.2 Global Myasthenia Gravis Disease Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Myasthenia Gravis Disease Drugs Revenue
3.4 Global Myasthenia Gravis Disease Drugs Market Concentration Ratio
3.4.1 Global Myasthenia Gravis Disease Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis Disease Drugs Revenue in 2020
3.5 Myasthenia Gravis Disease Drugs Key Players Head office and Area Served
3.6 Key Players Myasthenia Gravis Disease Drugs Product Solution and Service
3.7 Date of Enter into Myasthenia Gravis Disease Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Myasthenia Gravis Disease Drugs Breakdown Data by Type
4.1 Global Myasthenia Gravis Disease Drugs Historic Market Size by Type (2016-2021)
4.2 Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Type (2022-2027)

5 Myasthenia Gravis Disease Drugs Breakdown Data by Application
5.1 Global Myasthenia Gravis Disease Drugs Historic Market Size by Application (2016-2021)
5.2 Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Myasthenia Gravis Disease Drugs Market Size (2016-2027)
6.2 North America Myasthenia Gravis Disease Drugs Market Size by Type
6.2.1 North America Myasthenia Gravis Disease Drugs Market Size by Type (2016-2021)
6.2.2 North America Myasthenia Gravis Disease Drugs Market Size by Type (2022-2027)
6.2.3 North America Myasthenia Gravis Disease Drugs Market Size by Type (2016-2027)
6.3 North America Myasthenia Gravis Disease Drugs Market Size by Application
6.3.1 North America Myasthenia Gravis Disease Drugs Market Size by Application (2016-2021)
6.3.2 North America Myasthenia Gravis Disease Drugs Market Size by Application (2022-2027)
6.3.3 North America Myasthenia Gravis Disease Drugs Market Size by Application (2016-2027)
6.4 North America Myasthenia Gravis Disease Drugs Market Size by Country
6.4.1 North America Myasthenia Gravis Disease Drugs Market Size by Country (2016-2021)
6.4.2 North America Myasthenia Gravis Disease Drugs Market Size by Country (2022-2027)
6.4.3 United States
6.4.3 Canada

7 Europe
7.1 Europe Myasthenia Gravis Disease Drugs Market Size (2016-2027)
7.2 Europe Myasthenia Gravis Disease Drugs Market Size by Type
7.2.1 Europe Myasthenia Gravis Disease Drugs Market Size by Type (2016-2021)
7.2.2 Europe Myasthenia Gravis Disease Drugs Market Size by Type (2022-2027)
7.2.3 Europe Myasthenia Gravis Disease Drugs Market Size by Type (2016-2027)
7.3 Europe Myasthenia Gravis Disease Drugs Market Size by Application
7.3.1 Europe Myasthenia Gravis Disease Drugs Market Size by Application (2016-2021)
7.3.2 Europe Myasthenia Gravis Disease Drugs Market Size by Application (2022-2027)
7.3.3 Europe Myasthenia Gravis Disease Drugs Market Size by Application (2016-2027)
7.4 Europe Myasthenia Gravis Disease Drugs Market Size by Country
7.4.1 Europe Myasthenia Gravis Disease Drugs Market Size by Country (2016-2021)
7.4.2 Europe Myasthenia Gravis Disease Drugs Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size (2016-2027)
8.2 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Type
8.2.1 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Type (2016-2027)
8.3 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Application
8.3.1 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Application (2016-2027)
8.4 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Region
8.4.1 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Myasthenia Gravis Disease Drugs Market Size (2016-2027)
9.2 Latin America Myasthenia Gravis Disease Drugs Market Size by Type
9.2.1 Latin America Myasthenia Gravis Disease Drugs Market Size by Type (2016-2021)
9.2.2 Latin America Myasthenia Gravis Disease Drugs Market Size by Type (2022-2027)
9.2.3 Latin America Myasthenia Gravis Disease Drugs Market Size by Type (2016-2027)
9.3 Latin America Myasthenia Gravis Disease Drugs Market Size by Application
9.3.1 Latin America Myasthenia Gravis Disease Drugs Market Size by Application (2016-2021)
9.3.2 Latin America Myasthenia Gravis Disease Drugs Market Size by Application (2022-2027)
9.3.3 Latin America Myasthenia Gravis Disease Drugs Market Size by Application (2016-2027)
9.4 Latin America Myasthenia Gravis Disease Drugs Market Size by Country
9.4.1 Latin America Myasthenia Gravis Disease Drugs Market Size by Country (2016-2021)
9.4.2 Latin America Myasthenia Gravis Disease Drugs Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size (2016-2027)
10.2 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Type
10.2.1 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Type (2016-2027)
10.3 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Application
10.3.1 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Application (2016-2027)
10.4 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Country
10.4.1 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 GlaxoSmithKline
11.1.1 GlaxoSmithKline Company Details
11.1.2 GlaxoSmithKline Business Overview
11.1.3 GlaxoSmithKline Myasthenia Gravis Disease Drugs Introduction
11.1.4 GlaxoSmithKline Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021)
11.1.5 GlaxoSmithKline Recent Development
11.2 Novartis
11.2.1 Novartis Company Details
11.2.2 Novartis Business Overview
11.2.3 Novartis Myasthenia Gravis Disease Drugs Introduction
11.2.4 Novartis Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021)
11.2.5 Novartis Recent Development
11.3 Teva Pharmaceutical
11.3.1 Teva Pharmaceutical Company Details
11.3.2 Teva Pharmaceutical Business Overview
11.3.3 Teva Pharmaceutical Myasthenia Gravis Disease Drugs Introduction
11.3.4 Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021)
11.3.5 Teva Pharmaceutical Recent Development
11.4 Roche
11.4.1 Roche Company Details
11.4.2 Roche Business Overview
11.4.3 Roche Myasthenia Gravis Disease Drugs Introduction
11.4.4 Roche Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021)
11.4.5 Roche Recent Development
11.5 Bristol-Myers Squibb
11.5.1 Bristol-Myers Squibb Company Details
11.5.2 Bristol-Myers Squibb Business Overview
11.5.3 Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Introduction
11.5.4 Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021)
11.5.5 Bristol-Myers Squibb Recent Development
11.6 Apotex
11.6.1 Apotex Company Details
11.6.2 Apotex Business Overview
11.6.3 Apotex Myasthenia Gravis Disease Drugs Introduction
11.6.4 Apotex Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021)
11.6.5 Apotex Recent Development
11.7 Cipla
11.7.1 Cipla Company Details
11.7.2 Cipla Business Overview
11.7.3 Cipla Myasthenia Gravis Disease Drugs Introduction
11.7.4 Cipla Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021)
11.7.5 Cipla Recent Development
11.8 Biogen
11.8.1 Biogen Company Details
11.8.2 Biogen Business Overview
11.8.3 Biogen Myasthenia Gravis Disease Drugs Introduction
11.8.4 Biogen Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021)
11.8.5 Biogen Recent Development
11.9 AbbVie
11.9.1 AbbVie Company Details
11.9.2 AbbVie Business Overview
11.9.3 AbbVie Myasthenia Gravis Disease Drugs Introduction
11.9.4 AbbVie Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021)
11.9.5 AbbVie Recent Development
11.10 Bausch Health
11.10.1 Bausch Health Company Details
11.10.2 Bausch Health Business Overview
11.10.3 Bausch Health Myasthenia Gravis Disease Drugs Introduction
11.10.4 Bausch Health Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021)
11.10.5 Bausch Health Recent Development
11.11 Sun Pharmaceuticals
11.11.1 Sun Pharmaceuticals Company Details
11.11.2 Sun Pharmaceuticals Business Overview
11.11.3 Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Introduction
11.11.4 Sun Pharmaceuticals Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021)
11.11.5 Sun Pharmaceuticals Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Myasthenia Gravis Disease Drugs Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Acetylcholinesterase Inhibitors
Table 3. Key Players of Immunosuppressant Drugs
Table 4. Key Players of Steroid
Table 5. Key Players of Others
Table 6. Global Myasthenia Gravis Disease Drugs Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 7. Global Myasthenia Gravis Disease Drugs Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Myasthenia Gravis Disease Drugs Market Size by Regions (2016-2021) & (US$ Million)
Table 9. Global Myasthenia Gravis Disease Drugs Market Share by Regions (2016-2021)
Table 10. Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 11. Global Myasthenia Gravis Disease Drugs Market Share by Regions (2022-2027)
Table 12. Myasthenia Gravis Disease Drugs Market Trends
Table 13. Myasthenia Gravis Disease Drugs Market Drivers
Table 14. Myasthenia Gravis Disease Drugs Market Challenges
Table 15. Myasthenia Gravis Disease Drugs Market Restraints
Table 16. Global Myasthenia Gravis Disease Drugs Revenue by Players (2016-2021) & (US$ Million)
Table 17. Global Myasthenia Gravis Disease Drugs Market Share by Players (2016-2021)
Table 18. Global Top Myasthenia Gravis Disease Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease Drugs as of 2020)
Table 19. Ranking of Global Top Myasthenia Gravis Disease Drugs Companies by Revenue (US$ Million) in 2020
Table 20. Global 5 Largest Players Market Share by Myasthenia Gravis Disease Drugs Revenue (CR5 and HHI) & (2016-2021)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Myasthenia Gravis Disease Drugs Product Solution and Service
Table 23. Date of Enter into Myasthenia Gravis Disease Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Myasthenia Gravis Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 26. Global Myasthenia Gravis Disease Drugs Revenue Market Share by Type (2016-2021)
Table 27. Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 28. Global Myasthenia Gravis Disease Drugs Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 29. Global Myasthenia Gravis Disease Drugs Market Size Share by Application (2016-2021) & (US$ Million)
Table 30. Global Myasthenia Gravis Disease Drugs Revenue Market Share by Application (2016-2021)
Table 31. Global Myasthenia Gravis Disease Drugs Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 32. Global Myasthenia Gravis Disease Drugs Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 33. North America Myasthenia Gravis Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 34. North America Myasthenia Gravis Disease Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 35. North America Myasthenia Gravis Disease Drugs Market Size by Application (2016-2021) (US$ Million)
Table 36. North America Myasthenia Gravis Disease Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 37. North America Myasthenia Gravis Disease Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 38. North America Myasthenia Gravis Disease Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 39. Europe Myasthenia Gravis Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 40. Europe Myasthenia Gravis Disease Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 41. Europe Myasthenia Gravis Disease Drugs Market Size by Application (2016-2021) (US$ Million)
Table 42. Europe Myasthenia Gravis Disease Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 43. Europe Myasthenia Gravis Disease Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 44. Europe Myasthenia Gravis Disease Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 45. Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 46. Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 47. Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Application (2016-2021) (US$ Million)
Table 48. Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 49. Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Region (2016-2021) & (US$ Million)
Table 50. Asia-Pacific Myasthenia Gravis Disease Drugs Market Size by Region (2022-2027) & (US$ Million)
Table 51. Latin America Myasthenia Gravis Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 52. Latin America Myasthenia Gravis Disease Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 53. Latin America Myasthenia Gravis Disease Drugs Market Size by Application (2016-2021) (US$ Million)
Table 54. Latin America Myasthenia Gravis Disease Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 55. Latin America Myasthenia Gravis Disease Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 56. Latin America Myasthenia Gravis Disease Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 57. Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Type (2016-2021) (US$ Million)
Table 58. Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Type (2022-2027) & (US$ Million)
Table 59. Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Application (2016-2021) (US$ Million)
Table 60. Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Application (2022-2027) & (US$ Million)
Table 61. Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Country (2016-2021) & (US$ Million)
Table 62. Middle East & Africa Myasthenia Gravis Disease Drugs Market Size by Country (2022-2027) & (US$ Million)
Table 63. GlaxoSmithKline Company Details
Table 64. GlaxoSmithKline Business Overview
Table 65. GlaxoSmithKline Myasthenia Gravis Disease Drugs Product
Table 66. GlaxoSmithKline Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021) & (US$ Million)
Table 67. GlaxoSmithKline Recent Development
Table 68. Novartis Company Details
Table 69. Novartis Business Overview
Table 70. Novartis Myasthenia Gravis Disease Drugs Product
Table 71. Novartis Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021) & (US$ Million)
Table 72. Novartis Recent Development
Table 73. Teva Pharmaceutical Company Details
Table 74. Teva Pharmaceutical Business Overview
Table 75. Teva Pharmaceutical Myasthenia Gravis Disease Drugs Product
Table 76. Teva Pharmaceutical Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021) & (US$ Million)
Table 77. Teva Pharmaceutical Recent Development
Table 78. Roche Company Details
Table 79. Roche Business Overview
Table 80. Roche Myasthenia Gravis Disease Drugs Product
Table 81. Roche Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021) & (US$ Million)
Table 82. Roche Recent Development
Table 83. Bristol-Myers Squibb Company Details
Table 84. Bristol-Myers Squibb Business Overview
Table 85. Bristol-Myers Squibb Myasthenia Gravis Disease Drugs Product
Table 86. Bristol-Myers Squibb Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021) & (US$ Million)
Table 87. Bristol-Myers Squibb Recent Development
Table 88. Apotex Company Details
Table 89. Apotex Business Overview
Table 90. Apotex Myasthenia Gravis Disease Drugs Product
Table 91. Apotex Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021) & (US$ Million)
Table 92. Apotex Recent Development
Table 93. Cipla Company Details
Table 94. Cipla Business Overview
Table 95. Cipla Myasthenia Gravis Disease Drugs Product
Table 96. Cipla Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021) & (US$ Million)
Table 97. Cipla Recent Development
Table 98. Biogen Company Details
Table 99. Biogen Business Overview
Table 100. Biogen Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021) & (US$ Million)
Table 101. Biogen Recent Development
Table 102. AbbVie Company Details
Table 103. AbbVie Business Overview
Table 104. AbbVie Myasthenia Gravis Disease Drugs Product
Table 105. AbbVie Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021) & (US$ Million)
Table 106. AbbVie Recent Development
Table 107. Bausch Health Company Details
Table 108. Bausch Health Business Overview
Table 109. Bausch Health Myasthenia Gravis Disease Drugs Product
Table 110. Bausch Health Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021) & (US$ Million)
Table 111. Bausch Health Recent Development
Table 112. Sun Pharmaceuticals Company Details
Table 113. Sun Pharmaceuticals Business Overview
Table 114. Sun Pharmaceuticals Myasthenia Gravis Disease Drugs Product
Table 115. Sun Pharmaceuticals Revenue in Myasthenia Gravis Disease Drugs Business (2016-2021) & (US$ Million)
Table 116. Sun Pharmaceuticals Recent Development
Table 117. Research Programs/Design for This Report
Table 118. Key Data Information from Secondary Sources
Table 119. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Myasthenia Gravis Disease Drugs Market Share by Type: 2020 VS 2027
Figure 2. Acetylcholinesterase Inhibitors Features
Figure 3. Immunosuppressant Drugs Features
Figure 4. Steroid Features
Figure 5. Others Features
Figure 6. Global Myasthenia Gravis Disease Drugs Market Share by Application: 2020 VS 2027
Figure 7. Hospitals Case Studies
Figure 8. Clinics Case Studies
Figure 9. Others Case Studies
Figure 10. Myasthenia Gravis Disease Drugs Report Years Considered
Figure 11. Global Myasthenia Gravis Disease Drugs Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 12. Global Myasthenia Gravis Disease Drugs Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 13. Global Myasthenia Gravis Disease Drugs Market Share by Regions: 2020 VS 2027
Figure 14. Global Myasthenia Gravis Disease Drugs Market Share by Regions (2022-2027)
Figure 15. Global Myasthenia Gravis Disease Drugs Market Share by Players in 2020
Figure 16. Global Top Myasthenia Gravis Disease Drugs Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myasthenia Gravis Disease Drugs as of 2020
Figure 17. The Top 10 and 5 Players Market Share by Myasthenia Gravis Disease Drugs Revenue in 2020
Figure 18. Global Myasthenia Gravis Disease Drugs Revenue Market Share by Type (2016-2021)
Figure 19. Global Myasthenia Gravis Disease Drugs Revenue Market Share by Type (2022-2027)
Figure 20. North America Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 21. North America Myasthenia Gravis Disease Drugs Market Share by Type (2016-2027)
Figure 22. North America Myasthenia Gravis Disease Drugs Market Share by Application (2016-2027)
Figure 23. North America Myasthenia Gravis Disease Drugs Market Share by Country (2016-2027)
Figure 24. United States Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 25. Canada Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Europe Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Myasthenia Gravis Disease Drugs Market Share by Type (2016-2027)
Figure 28. Europe Myasthenia Gravis Disease Drugs Market Share by Application (2016-2027)
Figure 29. Europe Myasthenia Gravis Disease Drugs Market Share by Country (2016-2027)
Figure 30. Germany Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 31. France Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. U.K. Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. Italy Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Russia Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Nordic Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Asia-Pacific Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Myasthenia Gravis Disease Drugs Market Share by Type (2016-2027)
Figure 38. Asia-Pacific Myasthenia Gravis Disease Drugs Market Share by Application (2016-2027)
Figure 39. Asia-Pacific Myasthenia Gravis Disease Drugs Market Share by Region (2016-2027)
Figure 40. China Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 41. Japan Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. South Korea Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. Southeast Asia Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. India Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. Australia Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Latin America Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Myasthenia Gravis Disease Drugs Market Share by Type (2016-2027)
Figure 48. Latin America Myasthenia Gravis Disease Drugs Market Share by Application (2016-2027)
Figure 49. Latin America Myasthenia Gravis Disease Drugs Market Share by Country (2016-2027)
Figure 50. Mexico Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 51. Brazil Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Middle East & Africa Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Myasthenia Gravis Disease Drugs Market Share by Type (2016-2027)
Figure 54. Middle East & Africa Myasthenia Gravis Disease Drugs Market Share by Application (2016-2027)
Figure 55. Middle East & Africa Myasthenia Gravis Disease Drugs Market Share by Country (2016-2027)
Figure 56. Turkey Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 57. Saudi Arabia Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. UAE Myasthenia Gravis Disease Drugs Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. GlaxoSmithKline Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2016-2021)
Figure 60. Novartis Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2016-2021)
Figure 61. Teva Pharmaceutical Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2016-2021)
Figure 62. Roche Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2016-2021)
Figure 63. Bristol-Myers Squibb Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2016-2021)
Figure 64. Apotex Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2016-2021)
Figure 65. Cipla Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2016-2021)
Figure 66. Biogen Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2016-2021)
Figure 67. AbbVie Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2016-2021)
Figure 68. Bausch Health Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2016-2021)
Figure 69. Sun Pharmaceuticals Revenue Growth Rate in Myasthenia Gravis Disease Drugs Business (2016-2021)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed

---